Development of a Conceptual Model for the Patient Experience of Focal Segmental Glomerulosclerosis (FSGS): A Qualitative Targeted Literature Review.

Autor: Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate, London, UK. natalie.aldhouse@clarivate.com., Kitchen H; Clinical Outcomes Assessment, Clarivate, London, UK., Al-Zubeidi T; Clinical Outcomes Assessment, Clarivate, London, UK., Thursfield M; Clinical Outcomes Assessment, Clarivate, London, UK., Winnette R; Pfizer Inc, New York, NY, USA., See Tai S; Pfizer Inc, Collegeville, PA, USA., Zhu L; Pfizer Inc, Collegeville, PA, USA., Garnier N; Pfizer Inc, Collegeville, PA, USA., Baker CL; Pfizer Inc, New York, NY, USA.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2023 Dec; Vol. 40 (12), pp. 5155-5167. Date of Electronic Publication: 2023 Oct 11.
DOI: 10.1007/s12325-023-02651-6
Abstrakt: Introduction: Focal segmental glomerulosclerosis (FSGS) is a leading cause of kidney disease and can progress to end stage kidney disease (ESKD). An overview of symptoms and impacts of the disease experienced will help inform the selection or development of fit-for-purpose clinical outcome assessments (COA) to be used in FSGS clinical trials. This study aimed to develop a conceptual model (CM) of the adult and pediatric patient experience of FSGS including disease signs/symptoms, treatment side-effects, and impact on functioning and wellbeing.
Methods: This study comprised a systematic review and thematic analysis of qualitative studies with adults and pediatric patients diagnosed with FSGS. Data sources were identified through an electronic database search of journal articles (Medline, Embase, PsycINFO; June 2021) and hand-searching of conference proceedings, patient advocacy group websites, and gray literature. Non-English articles were excluded. Identified data (patient/caregiver quotes, author summaries, and interpretations of patient experiences) were extracted from the articles. Extracted data were qualitatively analyzed aided by ATLAS.ti v7. Codes were applied to data and concepts (symptoms/impacts) were identified, named, and refined. A CM was developed by grouping related concepts into domains.
Results: In total, 12 sources were identified for analysis: 6 journal articles and 6 series of patient testimonials. Salient sign/symptom/side-effect domains included swelling/puffiness (edema), pain/aches/discomfort, fatigue, weight changes, skin problems, respiratory problems, and sleep problems. Salient impact domains included emotional/psychological wellbeing, physical functioning/activities of daily living, social functioning, and work/school.
Conclusion: Secondary analysis of published qualitative literature permitted development of a CM describing the adult and pediatric experience of FSGS. Concept elicitation interviews are recommended to refine the CM, confirm the salient/most bothersome concepts, and confirm the extent of impact on daily life. The refined CM will provide a useful tool to inform the selection, development, and/or amendment of COAs for use in future FSGS clinical trials.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: